Skip to main content
Premium Trial:

Request an Annual Quote

LGC to Use Fluidigm's BioMark System in UK Labs

NEW YORK (GenomeWeb News) – The life sciences services firm LGC has purchased one of Fluidigm’s BioMark Systems, which it will use to offer genetic analysis services in its United Kingdom labs, Fluidigm said today.
The BioMark System uses fluidic circuit technology to improve throughput, reduce complexity, and allow for use of smaller samples and less reagents in high throughput genotyping applications, the company said.
With the purchase, LGC will add digital PCR to the other services, including quantitative PCR, genotyping, gene expression, copy number variation, and absolute quantification for sequencing, it offers to UK biotech research customers.
Fluidigm said that LGC initially will use the Fluidigm’s integrated fluidic circuitry system in PCR and gene expression projects in its Research & Technology Division, but in the future will include it in its LGC Standards, Life & Food Sciences, and LGC Forensics divisions as well.
“The system will initially be used by the scientific teams in LGC's Research & Technology Division to look at the accurate quantification of rare target sequences for applications such as health diagnostics and monitoring the efficiency of drug therapies," Derek Craston, who directs LGC’s R&T division, said in a statement.
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.